<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>
    <title>OSS on BullSignal | Global Market Intelligence</title>
    <link>https://www.bullsignal.net/en/tags/oss/</link>
    <description>Recent content in OSS on BullSignal | Global Market Intelligence</description>
    <generator>Hugo -- 0.154.5</generator>
    <language>en</language>
    <lastBuildDate>Sat, 11 Jul 2026 23:42:08 +0800</lastBuildDate>
    <atom:link href="https://www.bullsignal.net/en/tags/oss/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>📌 X Insight Update[x_fin] (2026/07/11 21:41)</title>
      <link>https://www.bullsignal.net/en/posts/20260711_234208/</link>
      <pubDate>Sat, 11 Jul 2026 23:42:08 +0800</pubDate>
      <guid>https://www.bullsignal.net/en/posts/20260711_234208/</guid>
      <description>S&amp;amp;P Bank Index is the chart that matters most right now. The breakout above pre-Great Financial Crisis highs has held, and this week closed at another new all-time high.</description>
    </item>
    <item>
      <title>📌 X Insight Update[x_fin] (2026/06/27 20:31)</title>
      <link>https://www.bullsignal.net/en/posts/20260627_220204/</link>
      <pubDate>Sat, 27 Jun 2026 22:02:04 +0800</pubDate>
      <guid>https://www.bullsignal.net/en/posts/20260627_220204/</guid>
      <description>CBRS may have a near-term catalyst: GPT’s official post quietly points to GPT5.6 launching on the Cerebras platform in July , with up to 750 tokens/second for selected customers.</description>
    </item>
    <item>
      <title>📌 X Insight Update[x_fin] (2026/06/17 00:04)</title>
      <link>https://www.bullsignal.net/en/posts/20260617_005410/</link>
      <pubDate>Wed, 17 Jun 2026 00:54:10 +0800</pubDate>
      <guid>https://www.bullsignal.net/en/posts/20260617_005410/</guid>
      <description>Innovative drugs need a cautious setup. The 2025 bull run was driven by the BD wave, because China’s innovative-drug R&amp;amp;D assets could exit across the full lifecycle, similar to th…</description>
    </item>
  </channel>
</rss>
